Company Overview - 康希诺生物股份公司 is located in Tianjin Economic-Technological Development Area and was established on January 13, 2009. The company went public on August 13, 2020. Its main business involves the research, production, and commercialization of innovative vaccines that meet both Chinese and international standards [1][2]. Financial Performance - As of June 30, 康希诺 reported a revenue of 382 million yuan for the first half of 2025, representing a year-on-year growth of 26% [2]. - The company experienced a net profit attributable to shareholders of -13.49 million yuan, which is a 94.02% increase in losses compared to the previous period [2]. - Since its A-share listing, 康希诺 has distributed a total of 198 million yuan in dividends, with no dividends paid in the last three years [3]. Stock Performance - On September 4, 康希诺's stock price decreased by 2.00%, trading at 82.15 yuan per share, with a total market capitalization of 20.33 billion yuan [1]. - Year-to-date, the stock has increased by 34.56%, with a 1.06% rise over the last five trading days, a 4.48% decline over the last 20 days, and a 32.33% increase over the last 60 days [1]. - The stock's trading volume showed a net outflow of 8.46 million yuan from main funds, with significant selling pressure observed [1]. Shareholder Information - As of June 30, 康希诺 had 17,500 shareholders, a decrease of 1.92% from the previous period, with an average of 0 circulating shares per shareholder [2]. Business Segments - The company's revenue composition is primarily from vaccine and related product sales, accounting for 97.84%, while other supplementary income makes up 2.16% [1]. - 康希诺 operates within the pharmaceutical and biotechnology sector, specifically in the vaccine sub-industry, and is involved in concepts such as anti-influenza and monkeypox [1].

Core Viewpoint - Cansino Biologics will participate in the 2025 Tianjin Listed Companies Investor Online Reception Day and Semi-Annual Performance Briefing to enhance interaction with investors and discuss key topics such as semi-annual performance, corporate governance, development strategy, and operational status [3][4]. Group 1 - Meeting Date and Time: The event is scheduled for September 11, 2025, from 15:00 to 17:00 [2][4]. - Meeting Format: The event will be held online, allowing investors to participate via the "Panorama Roadshow" website, WeChat, or the Panorama Roadshow APP [2][4]. - Participants: The meeting will include key company personnel such as the Chairman and General Manager Xuefeng Yu, Board Secretary Cui Jinxian, and Acting Financial Officer Liu Ming [5]. Group 2 - Contact Information: Investors can reach out to the Board Office for inquiries via phone at 022-58213766 or email at ir@cansinotech.com [6]. - Announcement Date: The announcement was made on September 3, 2025 [8].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | ...

证券代码：688185 证券简称：康希诺 公告编号：2025-022 康希诺生物股份公司 关于参加 2025 年天津辖区上市公司投资者网上集体接待日 暨半年报业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开方式：本次活动将采用网络远程的方式举行，投资者可以登录"全景 路演"（http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP，参与本次互动交流。 一、会议类型 为进一步加强与投资者的互动交流，康希诺生物股份公司（以下简称"公司"）将 参加由天津证监局指导、天津上市公司协会及深圳市全景网络有限公司联合举办的 "2025 年天津辖区上市公司投资者网上集体接待日暨半年报业绩说明会"活动。公司将 围绕 2025 半年度业绩、公司治理、发展战略、经营状况等投资者关心的问题，通过 互动平台与投资者进行沟通交流。 二、会议召开的时间、方式 1、召开时间：2025 年 9 月 11 日（周四）15:00-17:00。 2、召开方式：本次活动将采用网络远程 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 於 本 公 告 日 期，本 公 司 董 事 會 包 括 執 行 董 事Xuefeng YU博 士、Shou Bai CHAO博 士及王靖女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建 忠先生及張耀樑先生。 证券代码：688185 证券简称：康希诺 公告编号：2025-022 （股份代號：6185） 海外監管公告 本 公 告 乃 康 希 諾 生 物 股 份 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市規則第13.10B條而發表。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 發 的《康 希 諾 生 物 股 份 公 司 關 於 參 加2025 年 天 津 轄 區 上 市 公 司 投 資 者 網 上 集 體 接 待 日 暨 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Market Performance - The optical optoelectronics sector rose by 1.02% on September 1, with Tengjing Technology leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Stock Highlights - Tengjing Technology (688185) closed at 85.50, with a significant increase of 20.00% and a trading volume of 144,700 shares, amounting to a transaction value of 1.129 billion yuan [1] - Wenbisen (300389) saw a rise of 14.39%, closing at 18.05, with a trading volume of 473,000 shares [1] - Yongxin Optical (603297) increased by 10.00%, closing at 116.38, with a trading volume of 51,800 shares [1] - Wanrun Technology (002654) and Helitai (002217) also experienced notable gains of 9.98% and 9.97%, respectively [1] Fund Flow Analysis - The optical optoelectronics sector experienced a net inflow of 195 million yuan from institutional investors, while retail investors saw a net outflow of 162 million yuan [2] - The main funds showed a significant net inflow in stocks like Helitai (002217) and Wanrun Technology (002654), with net inflows of 74.4 million yuan and 44.2 million yuan, respectively [3] - Conversely, retail investors withdrew funds from several stocks, including Tengjing Technology, which saw a net outflow of 58.75 million yuan [3]

Core Viewpoint - 康希诺生物股份公司 is experiencing fluctuations in stock performance, with a notable increase in stock price year-to-date, but a recent decline in the short term [1][2]. Financial Performance - As of June 30, 康希诺 reported a revenue of 3.82 billion yuan for the first half of 2025, representing a year-on-year growth of 26% [2]. - The company recorded a net profit attributable to shareholders of -1348.54 million yuan, which is an increase in loss of 94.02% compared to the previous period [2]. Stock Market Activity - On August 29, 康希诺's stock price rose by 2.04% to 82.95 yuan per share, with a trading volume of 1.05 billion yuan and a turnover rate of 1.12%, leading to a total market capitalization of 205.26 billion yuan [1]. - The stock has increased by 35.87% year-to-date, but has seen a decline of 5.25% over the last five trading days [1]. Shareholder Information - As of June 30, 康希诺 had 17,500 shareholders, a decrease of 1.92% from the previous period [2]. - The average number of circulating shares per shareholder remained at 0 shares, indicating no change [2]. Dividend Information - 康希诺 has distributed a total of 1.98 billion yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].

Group 1 - The stock price of CanSino (688185.SH) closed at 80.87 yuan, reflecting a decline of 4.66% [1] - CanSino was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 13, 2020, with an issuance of 24.8 million shares at a price of 209.71 yuan per share [1] - The company raised a total of 5.201 billion yuan, with a net amount of 4.979 billion yuan after deducting issuance costs, which was 3.979 billion yuan more than the original plan [1] Group 2 - The funds raised were intended for several projects, including the construction of the second phase of the production base, vaccine development, cold chain logistics system, and working capital [1] - The issuance costs for CanSino amounted to 221 million yuan, with underwriting fees accounting for 205 million yuan [2] - CITIC Securities, as the lead underwriter, received an allocation of 496,000 shares, representing 2.00% of the total shares issued, with an investment amount of 104 million yuan [2]

Market Overview - The biopharmaceutical sector experienced a decline of 2.85% on August 27, with Kanghua Biotech leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Wuwei Biotech (300357) saw a significant increase of 5.38%, closing at 30.95 with a trading volume of 299,000 shares and a transaction value of 915 million yuan [1] - Kanghua Biotech (300841) reported a notable decline of 8.89%, closing at 76.60 with a trading volume of 125,200 shares and a transaction value of 993 million yuan [2] - Anke Biotech (300009) also faced a drop of 5.59%, closing at 11.14 with a trading volume of 862,300 shares and a transaction value of 990 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 1.853 billion yuan from institutional investors, while retail investors saw a net inflow of 1.543 billion yuan [2] - The capital flow for individual stocks indicates that Hualan Biotech (002007) had a net inflow of 32.28 million yuan from institutional investors, while it faced a net outflow of 40.67 million yuan from speculative funds [3] - The overall trend shows that retail investors are actively investing in the sector despite the institutional outflows [2][3]